Add Yahoo as a preferred source to see more of our stories on Google. Hutchmed's fruquintinib and Eli Lilly & Innovent Biologics' Tyvyt (sintilimab) significantly improved PFS during a Phase III trial ...
Serial metastasis-directed radiotherapy extended time off systemic therapy while maintaining favorable progression-free and overall survival in patients with oligometastatic clear-cell renal cell ...
Dose finding study of CBM588 in combination with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma: A phase I study. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Less than half of the healthcare providers correctly identified refractory chronic cough (RCC) as a cough lasting more than 8 weeks and not responding to treatment, based on survey data from more than ...
VORSIN-RCC: Vorolanib plus sintilimab for advanced renal cell carcinoma after failure of prior immune checkpoint inhibitors-based combination therapy. Background: At diagnosis, 55% of RCC are ...
Data from the FRUSICA-2 trial may support fruquintinib/sintilimab as a “valuable” option for patients with advanced renal cell carcinoma. Combining fruquintinib ...
Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium. Ensuring optimal treatment strategies for renal cell carcinoma (RCC) remains a key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results